Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ACCG-2671
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Structure Therapeutics Picks ACCG-2671 Amylin Agonist for Obesity Treatment
Details : ACCG-2671 is an oral small molecule amylin receptor agonist, which is currently being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : ACCG-2671
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Structure Therapeutics Doses First Patients in Phase 2b GSBR-1290 Study
Details : GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target which is being evaluated for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Goldman Sachs & Co
Deal Size : Undisclosed
Deal Type : Public Offering
Structure Therapeutics Closes Upsized Public Offering with Additional Shares Option
Details : The net proceeds will be used to fund the GSBR-1290 an orally-available small molecule agonist of the GLP-1 receptor, which is being evaluated for the treatment of T2DM and obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 06, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Goldman Sachs & Co
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Goldman Sachs & Co
Deal Size : $547.4 million
Deal Type : Public Offering
Structure Closes Upsized Offering, Fully Exercised Underwriter Option
Details : The net proceeds will be used to fund the GSBR-1290 an orally-available small molecule agonist of the GLP-1 receptor, which is being evaluated for the treatment of T2DM and obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 06, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Goldman Sachs & Co
Deal Size : $547.4 million
Deal Type : Public Offering
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Structure Therapeutics Reports Positive Data from Phase 2a Obesity Study
Details : GSBR-1290 is a oral non-peptide small molecule GLP-1 receptor agonist which is being evaluated for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Structure's Diabetes Pill Misses Weight-Loss Expectations in Mid-stage Trial
Details : GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target which is being evaluated for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : GSBR-1290
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of) T2DM and obesity. The Company is also planning a separate formulation bridging pharmacokinetic study to support the planned trans...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2023
Lead Product(s) : GSBR-1290
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable